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Abstract
Background: Bravecto™ Chewable Tablets for Dogs, containing fluralaner as active ingredient, is an innovative
treatment for flea and tick infestations that provides safe, rapid and long acting efficacy after a single oral
administration in dogs. Topically applied fluralaner provides similar safe, rapid and long acting efficacy, both in dogs
and in cats. The pharmacokinetic profile of fluralaner was evaluated in dogs and in cats following either topical or
intravenous administration.
Methods: Twenty four dogs and 24 cats received three different topical doses, with the mid-dose based on the
respective minimum recommended dose, and one intravenous dose. Plasma samples were collected for 112 days
and fluralaner concentrations were quantified using a validated high performance liquid chromatography
with tandem mass spectrometry (HPLC-MS/MS) method. Pharmacokinetic parameters were calculated using
non-compartmental methods.
Results: In dogs, fluralaner was readily absorbed from the topical administration site into the skin, subjacent tissues
and blood. Fluralaner plasma concentrations showed an apparent plateau between ~ day 7 and 63, with individual
tmax seen within this time period. After the plasma plateau, concentrations declined slowly and were quantifiable
for more than 12 weeks. In cats, fluralaner was readily systemically absorbed from the topical administration site,
reaching maximum concentrations (Cmax) in plasma between 3 and 21 days post administration, after which
concentrations declined slowly, and were also quantifiable for more than 12 weeks. Systemic exposure, as shown
by Cmax and the area under the concentration versus time curve from time 0 to the last measurable concentration
(AUC(0→t)) increased proportionally with dose in both species. Following intravenous administration fluralaner
showed a relatively high apparent volume of distribution (Vz), a low plasma clearance (Cl), a long terminal half-life
(t1/2) and a long mean residence time (MRT); thereby demonstrating a long persistence of fluralaner in both species.
Conclusions: The pharmacokinetic characteristics of fluralaner explain its prolonged activity against fleas and ticks
on both dogs and cats after a single topical administration.
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Background
Bravecto™ Chewable Tablets for Dogs, containing fluralaner
as active ingredient, is an innovative commercially available
treatment for flea and tick infestations that provides
safe, rapid and long acting efficacy after a single oral
administration in dogs [1–4]. The active ingredient
fluralaner belongs to the isoxazolines, a new class of
compounds with potent antiparasitic activity. Flurala-
ner has activity against γ-aminobutyric acid- (GABA-)
and glutamate-gated chloride channels with significant
selectivity for insect neurons over mammalian neurons
[5], which is predictive of the wide safety margin for
this antiparasitic compound. Even at much higher
than clinically relevant doses, fluralaner was well tolerated
[2]. Fluralaner has a high potency against ticks and fleas
by exposure via feeding, i.e. fleas and ticks that initiate
feeding will be exposed to the active ingredient [6].
A newly developed spot-on formulation of fluralaner
(Bravecto™ Spot-on Solution, MSD Animal Health) pro-
vides similar safe, rapid and long acting efficacy against
fleas and ticks on dogs and cats. A single fluralaner dose
administered topically at the minimum recommended
dose of 25 mg/kg body weight (BW) on dogs and
40 mg/kg BW on cats provides at least 12 weeks of flea-
and tick control. Only a short period of time is needed
to effectively kill fleas (≤ 8 h) and ticks (≤ 12 h) on topic-
ally treated dogs [7] and cats. The fast onset together with
the long duration of activity after a single topical adminis-
tration offers a more convenient choice over monthly flea
and tick control treatments that is expected to increase
pet owner compliance. Increased compliance helps to
reduce protection gaps that can occur with missed re-
administration of monthly remedies.
Bravecto™ Spot-on Solution offers an opportunity for
additional effective treatment. For example, the palat-
ability of the chew was found to be 92.5 % [8], therefore
a proportion of dogs may be easier to treat with a topical
formulation; in addition, dogs that must be kept on
allergen-restricted diets may be preferentially prescribed
a topical formulation. Bravecto™ Spot-on Solution will be
the only available isoxazoline-class active ingredient for
cats providing 12 weeks of systemic protection against
flea and tick infestations, thus satisfying an urgent need
among owners and veterinarians for effective and reli-
able persistent ectoparasite control in cats.
The pharmacokinetic profiles of fluralaner in dogs and
in cats following single topical administration describe
the rate of absorption, distribution and elimination and
provide insight crucial for understanding the onset, ex-
tent, and duration of efficacy.
Pharmacokinetic characteristics of topically applied
fluralaner (Bravecto™ Spot-on Solution) were therefore
investigated with a similar parallel group design in both
dogs and cats.
Methods
For both pharmacokinetic studies, animals were treated
with the product, Bravecto™ Spot-on Solution, produced
according to Good Manufacturing Practice [9]. Fluralaner
for intravenous (i.v.) injection was formulated as 2.5 %
solution in a PEG200 vehicle containing 10 % v/v water
for injection.
All studies were compliant with the principles of Good
Laboratory Practice [10]. The animal work was con-
ducted in compliance with applicable national legislation
and was reviewed and approved by the Animal Experi-
mentation Ethics Committee at ENVIGO CRS S.A.
In vivo phase
In the dog pharmacokinetic study 24 young healthy male
and female Beagle (age 12–17 months; weight 7.4–12.1 kg)
dogs were kept indoors in pens with sealed floors and indi-
vidually housed for 5 weeks following topical fluralaner
administration to avoid potential cross contamination be-
tween animals. After this 5-week period, dogs were penned
in groups of 3 of the same treatment group and sex. In the
cat pharmacokinetic study 24 young healthy male and fe-
male European short hair cats (age 9–11 months; weight
2.2–4.8 kg) were kept in individual cages to avoid potential
cross contamination between animals.
During the time where animals were single housed, they
had individual social contact with the caretaker, daily out-
side their pens/cages. Room environment was monitored
continuously in both studies, with a temperature of 15–
21 °C, relative humidity of 40–70 %, 10–20 air changes
per hour and a 12-h fluorescent light/12-h dark cycle.
Dogs and cats were fed once daily in the morning with a
standard diet and had ad libitum access to water.
Dogs and cats were randomized to four treatment
groups in each study (3 animals per sex per group),
within sex, and blocked by body weight to ensure a bal-
anced distribution.
One group of six animals was treated i.v. with a constant
rate infusion over 5 min using an automatic injection
system (KDS Model 200, KD Scientific Inc., Holliston,
USA) at a fluralaner dose of 12.5 mg/kg BW. The perfu-
sion rate per hour (mL/hr) was approximately 12 times
higher than the respective dose volume to ensure
complete administration within 5 min (dog i.v. data was
previously published in Kilp et al. [4]).
All topical doses were calculated using individual body
weights and the nominal content of fluralaner. In the
dog study fluralaner (Bravecto™ Spot-on Solution) was
administered topically to three groups of dogs at doses
of 12.5, 25 or 50 mg/kg BW and was administered in
one or several spots dorsally along the dogs’ back. The
first spot was administered between the shoulder blades
and the following spots, if necessary due to the treat-
ment volume required, were administered approximately
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5–10 cm caudal of the previously administered spot. In
the cat study fluralaner (Bravecto™ Spot-on Solution) was
administered topically at doses of 20, 40 or 80 mg/kg BW
and was administered in one or several spots dorsally
along the cat’s back. The first spot was administered at the
base of the skull and the following spots, if necessary, were
administered approximately 5–10 cm caudal of the previ-
ously administered spot.
Blood samples were collected from the jugular vein
into sodium-citrate tubes before and at 1, 3, 5, 7, 10, 14,
21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91, 98, 105 and
112 days after topical administration and 15 min, 2, 4
and 8 h, and 1, 2, 3, 4, 7, 14, 21, 28, 35, 49, 63, 77, 91
and 112 days after i.v. dosing. Plasma was harvested by
centrifugation and subsequently stored frozen (-75 °C ±
15 °C) in sterile plastic vials until analysis. The animals
were closely observed for 1 h after dosing and once daily
thereafter.
HPLC MS/MS Analysis
Plasma concentrations of fluralaner were measured using
a HPLC-MS/MS method, validated according to current
guidelines [11–13]. Plasma samples were extracted by pro-
tein precipitation with acetonitrile and diluted with 0.1 %
formic acid. The resultant solution was analysed quantita-
tively using automated solid phase extraction coupled to
HPLC-MS/MS (online SPE-HPLC-MS/MS). The linear
range of the method for determination of fluralaner was
10.0 to 2500 ng/ml, with a validated lower limit of quanti-
fication (LLOQ) of 10.0 ng/ml.
Pharmacokinetic analysis
Pharmacokinetic parameters for fluralaner were calcu-
lated using non-compartmental methods with the vali-
dated software WinNonlin® Professional Version 5.3
(Pharsight Corporation, California, USA). Cmax and time
to peak concentration (tmax) were observed values. The
t1/2 was calculated by linear regression using the slope of
the terminal segment of the semilogarithmic plasma
concentration versus time curve. The AUC(0→t) was cal-
culated using the linear trapezoidal rule. The AUC from
time 0 extrapolated to infinity (AUC(0→∞)) was deter-
mined as AUC(0→ t) + Ct/λz, where Ct is the plasma con-
centration at time t and λz is the first order rate
constant associated with the terminal (log-linear) por-
tion of the curve. Vz after i.v. administration, based on
the terminal phase was calculated as Dose/λz × AUC.
Total body clearance (Cl) after i.v. administration was
calculated using the ratio of Dose/AUC. Bioavailability
(F %) via the topical route was calculated using mean
AUC(0→t) as (AUC(0→t) topical/AUC(0→t) iv) × (Dose iv/
Dose topical) × 100. MRT extrapolated to infinity was
calculated as the ratio of AUMC/AUC; where AUMC is
the area under the first moment curve.
Dose proportionality was tested for exposure parameters
Cmax and AUC(0→t). For this purpose dose-normalized
(nominal dose) values were analysed using a one-way ana-
lysis of variance (ANOVA) where the exposure parameters
are the dependent variable and the nominal dose is the in-
dependent variable. The test model null hypothesis was
equal dose groups (level of significance α = 5 %); i.e. dose
proportional increase in exposure parameters Cmax and
AUC(0→t). If the null hypothesis cannot be rejected, there
is no evidence against fluralaner dose proportionality.
All data are expressed as arithmetic means, unless
otherwise stated. Individual values with a difference be-
tween AUC(0→∞) and AUC(0→t) greater than 20 % of
AUC(0→∞) and/or an adjusted r
2 (square of correlation
coefficient) of the terminal phase regression line <0.85
were considered unreliable and therefore not taken into
account for mean calculations. For graphical presenta-
tion of mean plasma concentrations of fluralaner, values
below LLOQ (10 ng/ml) were set to ½ LLOQ (5 ng/ml),
except when all values at a time point were below
LLOQ.
Results and Discussion
Pharmacokinetic profile of fluralaner in dogs and in cats
In the pharmacokinetic study in dogs, each of four groups
of six dogs was administered fluralaner topically at one of
the three target doses (12.5, 25, or 50 mg/kg) or i.v. at a
target dose of 12.5 mg/kg. In the pharmacokinetic study
in cats, each of four groups of six cats was administered
fluralaner topically at one of three target doses (20, 40, or
80 mg/kg) or i.v. at a target dose of 5 mg/kg. In both stud-
ies there were no clinical findings or adverse events fol-
lowing administration that could be related to fluralaner.
After topical administration on dogs, fluralaner pene-
trates rapidly into the skin and subjacent tissues in suffi-
cient quantity to ensure fast onset of effective killing of
fleas (≤ 8 h) and ticks (≤ 12 h) exposed to fluralaner by
feeding [6, 7]. Repeated intensive shampooing beginning
3 days after topical administration did not impair flea
and tick efficacy over 12 weeks [14]. As fluralaner has a
low contact exposure activity compared to a high activity
following parasite feeding exposure [6], this is consistent
with rapid penetration into the skin and distribution to
related tissue fluids and blood where fluralaner can exert
its activity against ectoparasites, via feeding exposure.
Fluralaner plasma concentrations showed an apparent
plateau between ~ day 7 and 63, with individual tmax
seen within this time period.
After the plasma plateau, fluralaner concentrations de-
clined with quantifiable plasma concentrations detectable
for more than 12 weeks post administration. Following i.v.
administration the initial distribution of fluralaner was
rapid, followed by a long elimination phase (Fig. 1). After
both topical and i.v. administration some secondary peaks
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were present in the individual plasma concentration time
profiles, which may indicate redistribution or recirculation
e.g. enterohepatic re-circulation.
In cats, following topical administration, fluralaner was
readily absorbed, reaching individual maximum concen-
trations (tmax) in plasma between 3 and 21 days. After the
maximum concentration seen, fluralaner concentrations
progressively declined with quantifiable plasma concentra-
tions for more than 12 weeks post administration. Follow-
ing i.v. administration fluralaner initial distribution was
rapid, followed by a long elimination phase (Fig. 2).
Systemic bioavailability after topical administration was
calculated to be ~25 % in both dogs and cats. Increases in










































































Fig. 2 Mean plasma concentrations of fluralaner in cats following single topical and i.v. administration
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and AUC(0-t) appeared to be dose-proportional. No statis-
tically significant differences between dose groups in dose-
normalized exposure parameters AUC(0→t) and Cmax
(ANOVA, P = 0.533 (dogs)/0.866 (cats) for AUC(0→t) and
p–0.388 (dogs)/0.254 (cats) for Cmax), indicated no evi-
dence against the null hypothesis of fluralaner dose pro-
portionality, thereby showing linear kinetics over the dose
range of 12.5 to 50 mg/kg BW for dogs and of 20 to
80 mg/kg BW for cats.
Taking into account the total body water volume
(approximately 0.6 L/kg in dogs and 0.5 L/kg in cats)
[15], fluralaner shows a relatively high apparent distribu-
tion (Vz = 3.1 L/kg in dogs and 3.5 L/kg in cats) into tis-
sues following i.v. infusion [4]. This is expected because
the physicochemical properties of fluralaner with a
molecular weight of 556.29, an unionized state at physio-
logical pH (1–12), and a high logPow value of 5.35 [4, 5]
favour the ability to cross cell membranes.
For fluralaner, the main route of elimination is likely hep-
atic because the high plasma protein binding [4] indicates
minimal elimination via renal filtration. Plasma clearance
can therefore be assumed to be equivalent to hepatic clear-
ance. The clearance of fluralaner is low with only 0.14 L/
kg/day in dogs [4] and 0.23 L/kg/day in cats. Considering a
physiological hepatic blood flow of approximately 44.5 L/
kg/day in the dog or 38.6 L/kg/day in the cat [15] and as-
suming hepatic clearance of fluralaner of 0.14 L/kg/day and
0.23 L/kg/day, respectively, the hepatic extraction ratio for
fluralaner is estimated to be low (0.3 % in dogs [4] and
0.2 % in cats). The low clearance may be due to the high
Table 1 Mean (arithmetic) plasma pharmacokinetic parameters for fluralaner in dogs following single topical and i.v. administration
Parameters Topical Topical Topical Intravenousb
12.5 mg/kg 25.0 mg/kg 50.0 mg/kg 12.5 mg/kg
n = 6 n = 6 n = 6 n = 6
Cmax (ng/mL) 358 ± 94 727 ± 191 1698 ± 318 7109 ± 908
tmax
a (day) 42 (range 21–63) 25 (range 14–56) 25 (range 7–42) n/a
AUC(0→t) (day*ng/ml) 18933 ± 3599 41243 ± 7467 85852 ± 17283 87198 ± 11835
AUC(0→∞) (day*ng/ml) 19577 ± 3982 43375
c ± 8752 93468c ± 20424 87779 ± 12004
t1/2 (day) 17 ± 4 21
c ± 3 17c ± 3 15 ± 2
tlast (day) 112 ± 0 112 ± 0 112 ± 0 109 ± 9
MRT (day) 47 ± 1 48c ± 4 43c ± 6 20 ± 3
Cl (L/kg/day) n/a n/a n/a 0.14 ± 0.02
Vz (L/kg) n/a n/a n/a 3.1 ± 0.5
F (%) 22 ± 4 24 ± 4 25 ± 5 n/a
aMedian, other values are mean ± standard deviation
bData previously published in Kilp et al. [4]; cMean consits of n = 4 (50.0 mg/kg)/ n = 5 (25.0 mg/kg) values; other values excluded as considered unreliable; see
Methods
n/a - not applicable
Table 2 Mean (arithmetic) plasma pharmacokinetic parameters for fluralaner in cats following single topical and i.v. administration
Parameters Topical Topical Topical Intravenous
20.0 mg/kg 40.0 mg/kg 80.0 mg/kg 5.0 mg/kg
n = 6 n = 6 n = 6 n = 6
Cmax (ng/ml) 757 ± 328 1850 ± 808 2399 ± 865 4302 ± 435
tmax
a (day) 9 (range 5–10) 6 (range 3–14) 9 (range 7–21) n/a
AUC(0→t) (day*ng/ml) 22065 ± 7996 48161 ± 15294 89193 ± 21413 21863 ± 2160
AUC(0→∞) (day*ng/ml) 22276 ± 7996 48400 ± 15177 89690 ± 21479 22141 ± 2105
t1/2 (day) 13 ± 2 12 ± 4 12 ± 1 11 ± 1
tlast (day) 93 ± 14 102 ± 12 110 ± 6 68 ± 7
MRT (day) 24 ± 3 23 ± 7 29 ± 5 15 ± 1
Cl (L/kg/day) n/a n/a n/a 0.23 ± 0.02
Vz (L/kg) n/a n/a n/a 3.5 ± 0.5
F (%) 25 ± 9 28 ± 9 25 ± 6 n/a
aMedian, other values are mean ± standard deviation
n/a - not applicable
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protein binding of fluralaner, which limits the unbound
fraction of fluralaner in the vascular system that can be
presented to clearing organs and/or due to a low intrinsic
hepatic capacity to metabolize fluralaner [16–18].
As only unbound drugs in the vascular system are
available to clearing organs for elimination, apparent
volume of distribution (relatively high) and clearance
(low) are determinants of the terminal half-life [16–18].
Accordingly, mean t1/2, but also the MRT of fluralaner were
long. In both species, fluralaner could be quantified in
plasma for more than 12 weeks post administration, dem-
onstrating its long systemic persistence (Figs. 1 and 2).
The terminal plasma half-life was comparable follow-
ing topical and i.v. administration, indicating that the
terminal fluralaner plasma concentrations represented a
true elimination phase. MRT after topical administration
was considerably longer compared to i.v. administration
due to the prolonged absorption phase.
The non-compartmental pharmacokinetic parameters
calculated from the concentration–time data of fluralaner
are shown for dogs (Table 1) and cats (Table 2).
Comparison of the pharmacokinetic profile in dogs and cats
The pharmacokinetic profiles of cats and dogs are both
characterized by a long persistence of fluralaner. This is
due to a high plasma protein binding, relatively high vol-
ume of distribution and a very low clearance in both
species resulting in a long terminal half-life (11 days in
cats and 15 days in dogs) and MRT (15 days in cats and
20 days in dogs) of fluralaner.
Maximum fluralaner concentrations in plasma were
similar in dogs and cats at comparable topical dose
levels (Cmax 727 ng/ml in dogs at 25 mg/kg BW com-
pared to 757 ng/ml in cats at 20 mg/kg BW).
Although Cmax was similar at comparable topical dose
levels in both species, the extent of systemic exposure to
fluralaner in cats, as indicated by AUC, was approximately
half that in dogs. The plasma concentration profile in the
dog had an extended plateau between ~ day 7 and 63, whilst
in cats Tmax was seen sooner, followed by a longer and
slightly steeper terminal elimination phase, indicating both
faster absorption and faster elimination of fluralaner. This is
also reflected in the shorter terminal half-life and MRT
values in the cat after topical administration (12–13 and
23–29 days) compared to the dogs (17–21 and 43–48 days).
These results support the higher minimum recom-
mended topical fluralaner dose in cats (40 mg/kg BW)
compared with dogs (25 mg/kg BW) that delivers 12 weeks
of flea- and tick control.
Conclusion
The pharmacokinetic characteristics of fluralaner explain
its prolonged activity against fleas and ticks on both
dogs and cats after a single topical administration.
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